このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Zevra Therapeutics 将来の成長

Future 基準チェック /56

Zevra Therapeuticsは、65.3%と42%でそれぞれ年率65.3%で利益と収益が成長すると予測される一方、EPSはgrowで65.6%年率。

主要情報

65.3%

収益成長率

65.6%

EPS成長率

Pharmaceuticals 収益成長	27.6%
収益成長率	42.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	10 Jun 2024

今後の成長に関する最新情報

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 04

Recent updates

Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Apr 07

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 04

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Apr 02

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Dec 28

Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

Sep 05

This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

Aug 20

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

Apr 17

US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Mar 10

Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

Mar 08

Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

Nov 16

Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?

Nov 11

KemPharm posts Phase 1 data to support further studies for sleep disorder therapy

Sep 28

KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate

May 26

業績と収益の成長予測

NasdaqGS:ZVRA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	161	34	28	28	4
12/31/2025	96	-17	-9	-23	5
12/31/2024	28	-68	-42	-33	6
3/31/2024	28	-49	-46	-46	N/A
12/31/2023	27	-46	-34	-34	N/A
9/30/2023	17	-27	-22	-22	N/A
6/30/2023	17	-19	-24	-24	N/A
3/31/2023	9	-38	-19	-19	N/A
12/31/2022	10	-27	-19	-19	N/A
9/30/2022	11	-35	-15	-15	N/A
6/30/2022	10	-30	-11	-11	N/A
3/31/2022	20	-17	9	9	N/A
12/31/2021	29	-63	10	10	N/A
9/30/2021	28	-65	10	10	N/A
6/30/2021	28	-66	12	12	N/A
3/31/2021	23	-55	-3	-3	N/A
12/31/2020	13	-13	-2	-2	N/A
9/30/2020	12	-14	-4	-4	N/A
6/30/2020	22	-8	-5	-5	N/A
3/31/2020	15	-18	-15	-15	N/A
12/31/2019	13	-25	-24	-24	N/A
9/30/2019	11	-24	-36	-36	N/A
6/30/2019	N/A	-42	-49	-49	N/A
3/31/2019	N/A	-43	-51	-51	N/A
12/31/2018	N/A	-56	-54	-54	N/A
9/30/2018	N/A	-62	-46	-46	N/A
6/30/2018	N/A	-57	-40	-40	N/A
3/31/2018	N/A	-53	-38	-38	N/A
12/31/2017	N/A	-43	N/A	-33	N/A
9/30/2017	N/A	-43	N/A	-36	N/A
6/30/2017	N/A	-45	N/A	-34	N/A
3/31/2017	N/A	-30	N/A	-35	N/A
12/31/2016	N/A	-17	N/A	-30	N/A
9/30/2016	N/A	-16	N/A	-27	N/A
6/30/2016	N/A	-13	N/A	-23	N/A
3/31/2016	N/A	-52	N/A	-20	N/A
12/31/2015	N/A	-55	N/A	-20	N/A
9/30/2015	N/A	-57	N/A	-21	N/A
6/30/2015	N/A	-55	N/A	-20	N/A
3/31/2015	N/A	-29	N/A	-18	N/A
12/31/2014	N/A	-24	N/A	-15	N/A
9/30/2014	N/A	-14	N/A	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ZVRAは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: ZVRA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ZVRA今後 3 年以内に収益を上げることが予想されます。

収益対市場: ZVRAの収益 ( 42% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ZVRAの収益 ( 42% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ZVRAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Zevra Therapeutics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased by 9.1% to US$17.50

Consensus EPS estimates fall by 50%

Forecast breakeven date pushed back to 2026

No longer forecast to breakeven

Consensus revenue estimates increase by 18%

Recent updates

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia At Sleep 2024 Annual Meeting

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zevra Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Zevra Therapeutics, Inc., Annual General Meeting, May 13, 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Price target decreased by 9.1% to US$17.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 50%

Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia

Zevra Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast breakeven date pushed back to 2026

Zevra Therapeutics, Inc. Appoints Alvin Shih to the Board of Directors

Zevra Therapeutics, Inc. Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Zevra Therapeutics, Inc. Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

No longer forecast to breakeven

Zevra Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zevra Therapeutics, Inc. Announces Executive Changes

Zevra Therapeutics, Inc. Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of Sdx, the Sole Active Pharmaceutical Ingredient in Kp1077, in Healthy Volunteers At Psych Congress 2023

Independent Director recently bought US$51k worth of stock

Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

Consensus revenue estimates increase by 18%

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Consensus revenue estimates increase by 27%

This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zevra Therapeutics, Inc. Announces Board Changes

High number of new directors

Consensus revenue estimates fall by 10%

Independent Director recently bought US$50k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zevra Therapeutics, Inc. Announces Change of CEO, Effective June 1, 2023

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

Price target decreased by 13% to US$16.80

US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

KemPharm, Inc. Appoints Daniel Gallo as Senior Vice President of Medical Affairs and Advocacy

KemPharm, Inc., Annual General Meeting, Apr 25, 2023

CEO & Director recently bought US$52k worth of stock

KemPharm, Inc. Announces Promotion of Sven Guenther to Chief Scientific Officer and Christal Mickle to Chief Product Development Officer

KemPharm, Inc. Appoints Richard W. Pascoe, as Chief Executive Officer

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

KemPharm, Inc. Appoints Christopher Posner as New Independent Director

KemPharm, Inc. Announces That the U.S. Food and Drug Administration (The FDA) Grants the Orphan Drug Designation to Serdexmethylphenidate

Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?

Kempharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (Sdx)

KemPharm posts Phase 1 data to support further studies for sleep disorder therapy

KemPharm wins Buy rating at Canaccord on CNS focus

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

KemPharm, Inc.(NasdaqGS:KMPH) dropped from Russell Microcap Value Index

KemPharm, Inc., Annual General Meeting, Jun 28, 2022

KemPharm, Inc. Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

Kempharm, Inc. Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate

KemPharm, Inc. Completes KP1077 Pre-IND Meeting Process with FDA

KemPharm, Inc. (NasdaqGS:KMPH) announces an Equity Buyback for $50 million worth of its shares.

Kempharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose Sdx”

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc

KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety

KemPharm exercises existing warrants and issues new ones in private placement

KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate